Expedited discovery of second generation NK-1 antagonists: identification of a nonbasic aryloxy substituent.
Solution-phase, parallel-synthesis techniques were used to optimize a series of nonbasic NK-1 antagonists, resulting in the identification of (R)-26, an orally bioavailable compound with subnanomolar potency.